China Biotechnology

Research Progress of Bacteria and Their Derivatives in the Combination Therapy of Tumors

PAN Wendi, ZHU Denghui, MAO Lijiang, SHAO Zhenping, ZHAO Kai

China Biotechnology, 2024, 44(12): 76-90. DOI: 10.13523/j.cb.2404030

细菌菌株	癌症类型	临床分期	开展时间	状态	参考文献
E. coli SYNB1891	转移性实体瘤、淋巴瘤	Phase 1	2019.11-2024.05	终止	[10]
E. coli Nissle	胃癌、结肠直肠癌	Phase 3	2016.03-2018.05	完成	https://classic.clinicaltrials. gov/ct2/home NCT02706184
S. typhimurium VNP20009	晚期或转移性癌症	Phase 1			[93]
S. typhimurium VNP20009	恶性黑色素瘤	Phase 1			[58]
S. typhimurium Saltikva	转移性胰腺癌	Phase 1, 2			[11]
L. monocytogenes JNJ-64041809	前列腺肿瘤	Phase 1	2015.12-2019.08	完成	[12]
L. monocytogenes	头颈癌、头颈部鳞状细胞癌 HPV阳性口咽鳞状细胞癌	Phase 2	2013.12-2022.09	完成	https://classic.clinicaltrials. gov/ct2/home NCT02002182
L. monocytogenes	宫颈癌	Phase 2			[92]
L. monocytogenes	晚期宫颈癌	Phase 3	2016.08-2023.03	终止	https://classic.clinicaltrials. gov/ct2/home NCT02853604
B. longum	实体瘤	Phase 1	2019.07-2021.03	终止	https://classic.clinicaltrials. gov/ct2/home NCT04025307
C. novyi-NT	恶性实体瘤	Phase 1	2013.08-2019.09	完成	[34]
Mycobacterium bovis VPM1002BC	膀胱癌	Phase1, 2	2015.02-2023.04	完成	[96-97]

Table 2 Clinical trials of bacterial therapy for tumors

Other figure/table from this article

Fig.1 Strategies of using bacteria and their derivatives in tumor therapy
Table 1 Engineered bacteria as drug carriers and combination therapy strategies for tumors